UMR 152 PHARMA-DEV, IRD, UPS, Université de Toulouse, Toulouse, France.
Faculté de Pharmacie, Université des Sciences des Techniques et des Technologies de Bamako (USTTB), BP 1805, Bamako, Mali.
Malar J. 2018 Feb 5;17(1):68. doi: 10.1186/s12936-018-2223-7.
Plasmodium falciparum malaria is still one of the most deadly pathology worldwide. Efficient treatment is jeopardized by parasite resistance to artemisinin and its derivatives, and by poor access to treatment in endemic regions. Anti-malarial traditional remedies still offer new tracks for identifying promising antiplasmodial molecules, and a way to ensure that all people have access to care. The present study aims to validate the traditional use of Terminalia macroptera, a Malian plant used in traditional medicine.
Terminalia macroptera was collected in Mali. Leaves (TML) and roots ethanolic extracts (TMR) were prepared and tested at 2000 mg/kg for in vivo acute toxicity in Albino Swiss mice. Antiplasmodial activity of the extracts was assessed against a chloroquine resistant strain P. falciparum (FcB1) in vitro. In vivo, anti-malarial efficacy was assessed by a 4-day suppressive test at 100 mg/kg in two malaria murine models of uncomplicated malaria (Plasmodium chabaudi chabaudi infection) and cerebral malaria (Plasmodium berghei strain ANKA infection). Constituents of TMR were characterized by ultra-high-performance liquid chromatography coupled to high resolution mass spectrometry. Top ranked compounds were putatively identified using plant databases and in silico fragmentation pattern.
Lethal dose of TML and TMR were greater than 2000 mg/kg in Albino Swiss mice. According to the OECD's Globally Harmonized System of Classification, both extracts are non-toxic orally. Antiplasmodial activity of T. macroptera extracts was confirmed in vitro against P. falciparum FcB1 strain with IC50 values of 1.2 and 1.6 µg/mL for TML and TMR, respectively. In vivo, oral administration of TML and TMR induced significant reduction of parasitaemia (37.2 and 46.4% respectively) in P. chabaudi chabaudi infected mice at the 7th day of infection compared to untreated mice. In the cerebral malaria experimental model, mice treated with TMR and TML presented respectively 50 and 66.7% survival rates at day 9 post-infection when all untreated mice died. Eleven major compounds were found in TMR. Among them, several molecules already known could be responsible for the antiplasmodial activity of the roots extract of T. macroptera.
This study confirms both safety and anti-malarial activity of T. macroptera, thus validating its traditional use.
恶性疟原虫疟疾仍然是全球最致命的疾病之一。寄生虫对青蒿素及其衍生物的耐药性以及在流行地区获得治疗的机会有限,使有效的治疗受到威胁。抗疟传统疗法仍然为寻找有前途的抗疟分子提供了新的途径,并确保所有人都能获得治疗。本研究旨在验证马里植物Terminalia macroptera 的传统用途,该植物在传统医学中被用于治疗疟疾。
在马里收集了 Terminalia macroptera。制备了叶(TML)和根乙醇提取物(TMR),并在 Albino Swiss 小鼠中以 2000mg/kg 的剂量进行了体内急性毒性测试。在体外,用氯喹抗性株 P. falciparum(FcB1)评估提取物的抗疟活性。在体内,通过在两种无并发症疟疾(感染 Plasmodium chabaudi chabaudi)和脑型疟疾(感染 Plasmodium berghei 株 ANKA)的疟疾小鼠模型中以 100mg/kg 的剂量进行为期 4 天的抑制试验,评估抗疟疗效。TMR 的成分通过超高效液相色谱与高分辨率质谱联用进行了表征。根据植物数据库和计算机碎片模式,对排名最高的化合物进行了推测鉴定。
TML 和 TMR 在 Albino Swiss 小鼠中的致死剂量大于 2000mg/kg。根据经济合作与发展组织(OECD)的全球协调统一分类系统,这两种提取物口服均无毒。T. macroptera 提取物对 P. falciparum FcB1 株的抗疟活性在体外得到了证实,TML 和 TMR 的 IC50 值分别为 1.2 和 1.6μg/mL。在体内,与未治疗的小鼠相比,TML 和 TMR 口服给药可使感染 P. chabaudi chabaudi 的小鼠在感染后第 7 天的寄生虫血症分别降低 37.2%和 46.4%。在脑型疟疾实验模型中,感染后第 9 天,TMR 和 TML 治疗的小鼠的存活率分别为 50%和 66.7%,而所有未治疗的小鼠均死亡。在 TMR 中发现了 11 种主要化合物。其中,一些已被证实的分子可能是 T. macroptera 根提取物抗疟活性的原因。
本研究证实了 T. macroptera 的安全性和抗疟活性,从而验证了其传统用途。